Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years

Diabetology and Metabolic Syndrome

Volumn 3, Issue 1, 2011, Pages

  Werner, Haim ^a   Chantelau, Ernst A ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO;

APOPTOSIS; DRUG ACTIVITY; DRUG METABOLISM; GENE EXPRESSION; HUMAN; IN VITRO STUDY; INTRACELLULAR SIGNALING; MITOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; THROMBOCYTE FUNCTION;

EID: 79959650451     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-3-13     Document Type: Review

References (74)

1. Insulin-structure, function, design. Brandenburg D, Exp Clin Endocrinol Diabetes 1999 107 Suppl 2 6 S12
2. In vitro bioactivity of insulin analogues: lipogenic and anti-lipolytic potency and their interaction with the effect of native insulin. Ellis MJ, Darby SC, Jones RH, Sönksen PH, Diabetologia 1978 15 403 410 10.1007/BF01219650 738550 (Pubitemid 9046991)
3. Superactive insulin. Burke GT, Hu SQ, Ohta N, Schwartz GP, Zong L, Katsoyannis PG, Biochem Biophys Res Commun 1990 173 982 987 10.1016/S0006- 291X(05)80882-4 2268358
4. Insulin analogues: action profiles beyond glycaemic control. Eckardt K, Eckel J, Arch Physiol Biochem 2008 114 45 53 10.1080/13813450801983369 18465358 (Pubitemid 351998754)
5. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ, Diabetologia 1991 34 307 313 10.1007/BF00405001 1713869
6. Hybrid molecules containing the A-domain of insulin-like growth factor-1 and the B-chain of insulin have increased mitogenic activity relative to insulin. Tseng LY, Schwartz GP, Sheikh M, Chen ZZ, Joshi S, Wang JF, Nissley SP, Burke GT, Katsoyannis PG, Rechler MM, Biochem Biophys Res Commun 1987 149 672 679 10.1016/0006-291X(87)90420-7 2447882 (Pubitemid 18023032)
7. Insulin analogues with improved absorption characteristics. Brange J, Hansen JF, Langkjaer L, Markussen J, Ribel U, Sorensen AR, Horm Metab Res 1992 Supplement Series No 26 125 130 (Pubitemid 23017885)
8. The impact of the chemical synthesis of insulins on the development of new pharmaceuticals. Hansen B, Akt Endokrin Stoffw 1990 11 212 214
9. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32] insulin (HOE 901) in muscle cells. Bähr M, Kolter T, Seipke G, Eckel J, Eur J Pharmacol 1997 320 259 265 10.1016/S0014-2999(96) 00903-X 9059862 (Pubitemid 27076754)
10. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. Bennet RG, Fawcett J, Kruer MC, Duckworth WC, Hamel FG, J Endocrinol 2003 177 399 405 10.1677/joe.0.1770399 12773120 (Pubitemid 36722295)
11. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Häring HU, Horm Metab Res 1998 30 123 129 10.1055/s-2007-978849 9566852 (Pubitemid 28172517)
12. Effect of insulin detemir, compared to human insulin, on 3T3-LI adipogenesis. Boehm A, Staiger H, Hennige AM, Haas C, Machicao F, Häring HU, Regul Pept 2008 151 160 163 10.1016/j.regpep.2008.05.005 18571747
13. Insulin-like growth factor 1 receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Chisalita SI, Arnqvist HJ, Am J Physiol Endocrinol Metab 2004 286 896 E 901
14. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-1. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR, J Clin Endocrinol Metab 2001 86 5838 5847 10.1210/jc.86.12.5838 11739448 (Pubitemid 33152632)
15. Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor 1. Ciaraldi TP, Phillips SA, Carter L, Aroda V, Mudaliar S, Henry RR, J Clin Endocrinol Metab 2005 90 5551 5558 10.1210/jc.2005-1007 16030168 (Pubitemid 41415457)
16. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Eckardt K, May C, Koenen M, Eckel J, Diabetologia 2007 50 2534 2543 10.1007/s00125-007-0815-9 17898992 (Pubitemid 350060636)
17. Proliferation of Colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Erbel S, Reers C, Eckstein VW, et al. Diabetes Care 2008 31 1105 1111 10.2337/dc07-2015 18316392
18. Insulin and analogue effects on protein degradation in different cell types-dissociation between binding and activity. Fawcett J, Hamel FG, Bennet RG, Vajo Z, Duckworth WC, J Biol Chem 2001 276 11552 11558 10.1074/jbc.M007988200 11116143
19. Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism. Fawcett J, Tsui BT, Kruer MC, Duckworth WC, Metabolism 2004 53 1037 1044 10.1016/j.metabol.2004.02.013 15281015 (Pubitemid 38988290)
20. Differences in cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC, Metabolism 1999 48 611 617 10.1016/S0026-0495(99)90059-8 10337862 (Pubitemid 29230522)
21. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Hansen BF, Danielsen GM, Drejer K, Sörensen AR, Wiberg FC, Klein HH, Lundemose AG, Biochem J 1996 315 271 279 8670118 (Pubitemid 26113562)
22. Safety analysis of basal insulins: mitogenic potency and receptor binding. Abstract. Hansen BF, Stidsen CE, Glendorf T, Lundby A, Hegelund AC, Bonnesen C, Diabetologia 2010 53 Suppl 1 22
23. Insulin glulisine. Insulin receptor signalling characteristics in vivo. Hennige AM, Lehmann R, Weigert C, Moeschel K, Schäuble M, Metzinger E, Lammers R, Häring HU, Diabetes 2005 54 361 366 15677493
24. Effects of new insulin analogues HMR1964(insulin glulisine) and HMR1423 on insulin receptors. Hennige A, Strack V, Metzinger E, Seipke G, Häring HU, Kellerer M, Diabetologia 2005 48 1891 1897 10.1007/s00125-005-1870-8 16052329 (Pubitemid 41317845)
25. pI-shifted insulin analogs with extended in vivo time action and favourable receptor selectivity. Kohn WD, Micanovic R, Myers SL, et al. Peptides 2007 28 935 948 10.1016/j.peptides.2007.01.012 17328992 (Pubitemid 46349342)
26. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Kurtzhals P, Schaffer L, Sorensen A, et al. Diabetes 2000 49 999 1005 10.2337/diabetes.49.6.999 10866053 (Pubitemid 30349423)
27. Mitogenic effects of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-1. Liefvendahl E, Arnquist HJ, Horm Metab Res 2008 40 369 374 10.1055/s-2008-1062739 18393172 (Pubitemid 351967126)
28. IGF-1 receptor-mediated signalling of the human insulin analogue HOE 901. Abstract. Liu L, Koenen M, Seipke G, Eckel J, Diabetologia 1997 40 Suppl 1 355
29. Insulin glargine and human insulin promote proliferation of human breast cancer cell line MDA-MB-231 independent of ERK pathway.Abstract. Liu S, Li Y, Liang Y, Fan X, Liang Q, Yan L, Diabetes 2010 59 Supplement 1 Abstract.No.2488-PO
30. High dose detemir inhibits proliferation of a human bladder cancer T24 cell line independent of Akt and ERK pathway. Abstract. Liu S, Li Y, Liang Y, Lin T, Diabetologia 2010 53 Suppl 1 305
31. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U, Diabetes Res Clin Pract 2011 91 177 182 10.1016/j.diabres.2010.11.009 21129803
32. Proliferative effects of insulin analogues on mammary epithelial cells. Mayer D, Shukla A, Enzmann H, Arch Physiol Biochem 2008 114 38 44 10.1080/13813450801900645 18465357 (Pubitemid 351998750)
33. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Mayer D, Chantelau E, Arch Physiol Biochem 2010 116 73 78 10.3109/13813451003631439 20199195
34. Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular cancer cells. Letter. Müller K, Weidinger C, Führer D, Diabetologia 2010 53 1001 1003 10.1007/s00125-010-1674-3 20179899
35. A novel insulin analog with unique properties. Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J, Diabetes 2003 52 2227 2238 10.2337/diabetes.52.9.2227 12941761 (Pubitemid 37059492)
36. [LysB3,GluB29] insulin: a novel insulin analog with enhanced -cell protective action. Rakatzi I, Seipke G, Eckel J, Biochem Biophys Res Commun 2003 310 852 859 10.1016/j.bbrc.2003.09.090 14550282 (Pubitemid 37188700)
37. Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. Russo I, Massucco P, Mattiello L, Cavalot F, Anfossi G, Trovati M, Thromb Res 2002 107 31 37 10.1016/S0049-3848(02)00182-2 12413586 (Pubitemid 35284423)
38. Comparison between the effects of the rapid recombinant insulin analog lispro (Lys B28, Pro B 29) and those of human regular insulin on platelet cyclic nucleotides and aggregation. Russo I, Massucco P, Mattiello L, Anfossi G, Trovati M, Thromb Res 2003 109 323 327 10.1016/S0049-3848(03)00255-X 12818257 (Pubitemid 36724828)
39. In vitro pharmacology studies with insulin glargine and human insulin: IGF-1 receptor binding and thymidine incorporation. Abstract. Sandow J, Seipke G, Diabetes 2001 50 Suppl 2 429
40. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R, Diabetologia 2010 53 1743 53 10.1007/s00125-010-1760- 6 20424816
41. Insulin analogues: analysis of proliferative potency and characterisation of receptors and signalling pathways activated in human mammary epithelial cells. Dissertation. Shukla A, Faculty of Natural Sciences Ruperto-Carola University of Heidelberg, Germany 2008
42. Analysis of signalling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D, Endocr Relat Cancer 2009 16 429 441 10.1677/ERC-08-0240 19153208
43. Proliferative effect of Apidra (insulin glulisine), a rapid acting insulin analogue on mammary epithelial cells. Shukla A, Enzmann H, Mayer D, Arch Physiol Biochem 2009 115 119 126 10.1080/13813450903008628 19480564
44. In vitro analysis of Lys(B28),Pro(B29) human insulin (LY 275585): comparison to human insulin in terms of insulin and IGF-1 receptor binding, glucose uptake into adipocytes and thymidine incorporation into smooth muscle cells. Slieker LJ, Sundell KL, Unpublished report on file at Lilly Research Laboratories, Preclinical Pharmacology Report no.7 1994
45. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Slieker LJ, Brooke GS, Di Marchi RD, et al. Diabetologia 1997 40 Suppl 2 54 S 61
46. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. Sommerfeld MR, Müller G, Tschank G, Seipke G, Habermann P, Kurrle R, Tennagels N, PLoS One 2010 5 3 9540 10.1371/journal.pone.0009540 20209060
47. Stimulation of glucose and amino acid transport and activation of the insulin signalling pathways by insulin lispro in L6 skeletal muscle cells. Somwar R, Sweeney G, Ramlai T, Klip A, Clin Ther 1998 20 125 140 10.1016/S0149-2918(98)80040-4 9522110 (Pubitemid 28126286)
48. Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Sorensen AR, Stidsen CE, Ribel U, Nishimura E, Sturis J, Jonassen I, Bouman SD, Kurtzhals P, Brand CL, Diabetes Obes Metab 2010 12 665 673 10.1111/j.1463-1326.2010.01206.x 20590743
49. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Staiger K, Staiger H, Schweitzer MA, Metzinger E, Balletshofer B, Häring HU, Kellerer M, Diabetologia 2005 48 1898 1905 10.1007/s00125-005-1874-4 16078017 (Pubitemid 41317846)
50. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Staiger K, Hennige AM, Staiger H, Häring HU, Kellerer M, Horm Metab Res 2007 39 65 67 10.1055/s-2007-957352 17226117 (Pubitemid 46535160)
51. Insulin glulisine-a comprehensive preclinical evaluation. Stammberger I, Seipke G, Bartels, Int J Toxicol 2006 25 25 33 10.1080/10915810500488379 16510354 (Pubitemid 43328851)
52. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagons-like peptide-1 receptor agonists and insulin analogues. Tews D, Werner U, Eckel J, Horm Metab Res 2008 40 172 180 10.1055/s-2008-1042426 18348079 (Pubitemid 351690520)
53. In vitro and in vivo potency of insulin analogues designed for clinical use. Volund A, Brange J, Drejer K, Jensen I, Markussen J, Ribel U, Sorensen AR, Schlichtkrull J, Diabetic Med 1991 8 839 847 10.1111/j.1464-5491.1991.tb02122.x 1663018
54. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T, Diabetes Res Clin Pract 2008 81 269 277 10.1016/j.diabres.2008.05.007 18585815
55. Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factors-1 (IGF-1) in human lung fibroblasts. Warnken M, Reitzenstein U, Sommer A, Fuhrmann M, Mayer P, Enzmann H, Juergens UR, Racke K, Naunyn-Schmied Arch Pharmacol 2010 382 511 524 10.1007/s00210-010-0561-2
56. Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H, Diabetes Metab Res Rev 2009 25 41 49 10.1002/dmrr.912 19145584
57. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-1 receptor. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H, Diabetologia 2010 53 2667 2675 10.1007/s00125-010-1899-1 20835859
58. Scientific Discussion of insulin aspart (NovoRapid). EMEA, 2010 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000258/WC500030369.pdf
59. Scientific Discussion of insulin detemir (Levemir). EMEA, 2010 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000528/WC500036658.pdf
60. Scientific Discussion of insulin glargine (Lantus). EMEA, 2010 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000284/WC500036075.pdf
61. Scientific Discussion of insulin glulisine (Apidra). EMEA, 2010 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000557/WC500025246.pdf
62. Scientific Discussion of insulin lispro (Humalog). EMEA, http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000088/WC500050329.pdf accessed 17.11.2010
63. Physiological concentrations of insulin induce cellular desensitization to the mitogenic effect of insulin-like growth factor 1. Conover AC, Clarkson JT, Bale LK, Diabetes 1994 43 1130 1137 10.2337/diabetes.43.9.1130 8070613 (Pubitemid 24265475)
64. Comparison of biologic potency of human insulin (recombinant DNA) and purified porcine insulin (PPI) on the rat and human adipocyte lipogenesis model. Khokher MA, Dandona P, Diabetes Care 1982 5 Suppl 2 102 103 6765517 (Pubitemid 13251453)
65. Committee for proprietary medicinal products CPMP:Points to consider document on the non-clinical assessment of the carcinogenic potential of insulin analogues. EMEA, Internet search: CPMP/SWP/372/01 2001 Issued in London 15
66. Insulin analogues with increased mitogenic potency- are they safe? Hansen BF, Horm Metab Res 2008 40 431 433 10.1055/s-2008-1062740 18418813 (Pubitemid 351967137)
67. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R, Endocrine Reviews 2009 30 586 623 10.1210/er.2008-0047 19752219
68. Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer. Zhang C, Hao L, Xiao Y, Ge H, Zhu Z, Luo Y, Zhang Y, Zhang Y, BMC Cancer 2010 10 184 10.1186/1471-2407-10-184 20459642
69. Insulin and its analogs: actions via insulin and IGF receptors. Vigneri R, Squatrito S, Sciacca L, Acta Diabetol 2010 47 271 278 10.1007/s00592-010- 0215-3 20730455
70. Diabetogenic glucose and insulin concentrations modulate transcriptom and protein levels involved in tumour cell migration, adhesion and proliferation. Masur K, Vetter C, Hinz A, Tomas N, Henrich H, Niggemann B, Zänker KS, Br J Cancer 2011 104 345 352 10.1038/sj.bjc.6606050 21179032
71. Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia. Leroy EC, Moore JH, Hu C, Martinez ME, Lance P, Duggan D, Thompson PA, Hum Genet 2011 129 503 512 10.1007/s00439-010-0942-0 21221997
72. Insulin glargine is more potent in activating the human IGF-1 receptor than human insulin and insulin detemir. Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SWJ, Hofland LJ, Janssen JAMJL, Growth Horm IGF Res 2010 20 427 431 10.1016/j.ghir.2010.10.002 21055982
73. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. Smeeton F, Shojaee Moradie F, Jones RH, Westergaard L, Haahr H, Umpleby AM, Russell-Jones DL, Diabetologia 2009 52 2317 2323 10.1007/s00125-009-1487-4 19707744
74. Tissue selectivity of insulin detemir action in vivo. Hennige AM, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, Häring HU, Diabetologia 2006 49 1274 1282 10.1007/s00125-006-0192-9 16570163